Palmar plantar erythrodysesthesia medical therapy
|
Palmar plantar erythrodysesthesia Microchapters |
|
Differentiating Palmar plantar erythrodysesthesia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Palmar plantar erythrodysesthesia medical therapy On the Web |
|
American Roentgen Ray Society Images of Palmar plantar erythrodysesthesia medical therapy |
|
Palmar plantar erythrodysesthesia medical therapy in the news |
|
Directions to Hospitals Treating Palmar plantar erythrodysesthesia |
|
Risk calculators and risk factors for Palmar plantar erythrodysesthesia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mandana Chitsazan, M.D. [2]
Overview
Dose reduction, lengthening the interval between dose administration, and ultimately drug withdrawal are the most effective strategies. Specific treatments include cooling the extremities during drug administration, vitamin B6, topical and oral corticosteroids, and topical 99% dimethyl sulfoxide.
Medical Therapy
- Dose reduction, lengthening the interval between drug administration, and ultimately drug withdrawal, if necessary, appear to be the most effective strategies.[1] [2] [3] [4][5] [6]
- These strategies do not seem to affect the effectiveness of capecitabine, however, for other drug regimens this might affect efficacy. [7] [8][5] [9] [10]
- Specific treatments include:
| Treatment | Has been tried for the treatment of the PPE caused by |
|---|---|
| Cooling the extremities during drug administration |
|
| Pyridoxine (vitamin B6) |
|
| Potent topical corticosteroids
(The best results have been demonstrated when used in conjunction with cold compresses and emollients) |
|
| Oral corticosteroids |
|
| Topical 99% dimethyl sulfoxide: 4 times daily for 14 days | Liposome-encapsulated doxorubicin |
References
- ↑ Lassere Y, Hoff P (2004). "Management of hand-foot syndrome in patients treated with capecitabine (Xeloda)". Eur J Oncol Nurs. 8 Suppl 1: S31–40. doi:10.1016/j.ejon.2004.06.007. PMID 15341880.
- ↑ Abushullaih S, Saad ED, Munsell M, Hoff PM (2002). "Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience". Cancer Invest. 20 (1): 3–10. PMID 11853000.
- ↑ Hansen RM, Quebbeman EJ, Ritch PS, Frick J, Anderson T (1987). "Continuous 5-fluorouracil infusion and pulse methotrexate/leucovorin for colorectal adenocarcinoma. A report of excessive toxicity". Am J Clin Oncol. 10 (3): 216–8. PMID 3496002.
- ↑ Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, VonRoenn J (1995). "Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy". Cancer. 75 (8): 2169–73. doi:10.1002/1097-0142(19950415)75:8<2169::aid-cncr2820750822>3.0.co;2-h. PMID 7697608.
- ↑ 5.0 5.1 Gerbrecht BM (2003). "Current Canadian experience with capecitabine: partnering with patients to optimize therapy". Cancer Nurs. 26 (2): 161–7. PMID 12660565.
- ↑ Nagore E, Insa A, Sanmartín O (2000). "Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management". Am J Clin Dermatol. 1 (4): 225–34. doi:10.2165/00128071-200001040-00004. PMID 11702367.
- ↑ Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C; et al. (1999). "Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer". J Clin Oncol. 17 (2): 485–93. doi:10.1200/JCO.1999.17.2.485. PMID 10080589.
- ↑ Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M; et al. (2002). "First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin". Ann Oncol. 13 (4): 566–75. doi:10.1093/annonc/mdf089. PMID 12056707.
- ↑ O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G; et al. (2002). "Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results". J Clin Oncol. 20 (12): 2812–23. doi:10.1200/JCO.2002.09.002. PMID 12065558.
- ↑ Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG (1989). "A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study". J Clin Oncol. 7 (4): 425–32. doi:10.1200/JCO.1989.7.4.425. PMID 2926468.